



Application No. (if known): 10/735,514

Attorney Docket No.: 03939/100M269-US1

## **Certificate of Express Mailing Under 37 CFR 1.10**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

EL996121360 WS

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	July 27, 2004
	Date

Signature .

Signature .

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental Information Disclosure Statement (2 pages); (PTO/SB/08a/b (List of References) 1 page; 11 Publications; and Postcard.

Express Mail Label No. Dated: \_\_\_\_\_

Docket No.: 03939/100M269-US1

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

factor Application of:

Daniel A. Moros

Application No.: 10/735,514

Confirmation No.: 1588

Filed: December 11, 2003

Art Unit: N/A

For:

METHOD OF TREATING MOVEMENT

DISORDERS USING BARBITURIC ACID

**DERIVATIVES** 

Examiner: Not Yet Assigned

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information

Application No.: 10/735,514 2 Docket No.: 03939/100M269-US1

Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed documents.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: July 27, 2004

Respectfully submitted,

Jonathan P. Mitchell, Ph.D.

Registration No.: 50,239 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

bstitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 1

ed to respond to a conection of information diffess it contains a valid civib control full bei.			
Complete if Known			
Application Number	10/735,514		
Filing Date	December 11, 2003		
First Named Inventor	Daniel A. Moros		
Art Unit	N/A		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	03939/100M269-US1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number Hind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
						ľ

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
1	1	Arch Otolaryngol, Vol. 110, June 1984, pp 394-397, "Spastic Dysphonia and Essential (Voice) Tremor Treated With Primidone", David E. Hartman, et al.				
2.	2	Journal of Neurology, Neurosurgery, and Psychiatry 1985;48:911-915, "Primidone in Essential Tremor of the Hands and Head: A Double Blind Controlled Clinical Study", Leslie J. Findley, et al.				
3. 4.	3	Neurology, 1985; 35:1874-1787, "Phenobarbitone in Essential Tremor", Leslie J. Findley, et al.				
4.	4	Journal of Neurology, Neurosurgery, and Psychiatry 1986;49:64-68, "A Comparison of Primidone, Propranolol, and Placebo in Essential Tremor, Using Quantitative Analysis", W.P. Gorman, et al.				
5.	5	Neurology, 1986; 36:121-124, "Efficacy of Primidone In Essential Tremor", William C. Koller, et al.				
6.	6	Clinical Neuropharmacology Vol. 10, No. 4,1987, pp. 342-350, "Essential Tremor Variants: Effect of Treatment, William C. Koller, et al.				
7.	7	Acta Neurol Scand., 1987:75:332-340, "Primidone and Propranolol in Essential Tremor: A Study Based on Quantitative Tremor Recording and Plasma Anticonvulsant Levels", P. Dietrichson, et al.				
8.	8	Neurology, 1988, 38:808-810, "Double-Blind Comparison of Primidone and Phenobarbital In Essential Tremor"; Enrico Sasso, et al.				
9	9	Clinical Neuropharmacology, Vol. 13, No. 3, 1990, pp 210-223, "Basic Mechanism of Action of Drugs Used in the Treatment of Essential Tremor", Xiao-Ming Guan, et al.				
10	10	Clinical Neuropharmacology, Vol. 13, No. 1, 1990, pp. 67-76, "Primidone in the Long-Term Treatment of Essential Tremor: A Prospective Study with Computerized Quantitative Analysis", Enrico Sasso, et al.				
11	11	Movement Disorders, Vol. 6, No. 1, 1991, pp. 65-68, "Quantitative Comparison of Barbiturates in Essential Hand and Head Tremor", Enrico Sasso, et al.				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

(W:\039	Date Considered